Yaron Werber
Stock Analyst at TD Cowen
(0.94)
# 3,657
Out of 4,873 analysts
38
Total ratings
25%
Success rate
-9.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWTX SpringWorks Therapeutics | Downgrades: Hold | $66 → $47 | $46.98 | +0.04% | 1 | Apr 29, 2025 | |
| ONC BeOne Medicines | Reiterates: Buy | $334 | $266.93 | +25.13% | 1 | Apr 24, 2025 | |
| FBRX Forte Biosciences | Initiates: Buy | n/a | $10.59 | - | 1 | Jan 21, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | n/a | $18.34 | - | 1 | Dec 20, 2024 | |
| SEPN Septerna | Initiates: Buy | n/a | $10.74 | - | 1 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $160 → $153 | $173.00 | -11.56% | 5 | Nov 15, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $132 → $122 | $104.63 | +16.60% | 5 | Nov 6, 2024 | |
| UPB Upstream Bio | Initiates: Buy | n/a | $10.91 | - | 1 | Nov 5, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $61 → $73 | $37.43 | +95.03% | 2 | Oct 21, 2024 | |
| EXEL Exelixis | Maintains: Buy | $27 → $34 | $43.53 | -21.89% | 2 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $59 | $40.01 | +47.48% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $67 | $33.47 | +100.18% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $11.81 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.57 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.02 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $21.46 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $612 → $641 | $560.53 | +14.36% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.36 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $375 → $625 | $5.71 | +10,845.71% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $26.91 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $20.53 | +85.09% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.51 | - | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.39 | - | 1 | Oct 26, 2021 |
SpringWorks Therapeutics
Apr 29, 2025
Downgrades: Hold
Price Target: $66 → $47
Current: $46.98
Upside: +0.04%
BeOne Medicines
Apr 24, 2025
Reiterates: Buy
Price Target: $334
Current: $266.93
Upside: +25.13%
Forte Biosciences
Jan 21, 2025
Initiates: Buy
Price Target: n/a
Current: $10.59
Upside: -
Dianthus Therapeutics
Dec 20, 2024
Initiates: Buy
Price Target: n/a
Current: $18.34
Upside: -
Septerna
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $10.74
Upside: -
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $173.00
Upside: -11.56%
BioNTech SE
Nov 6, 2024
Maintains: Hold
Price Target: $132 → $122
Current: $104.63
Upside: +16.60%
Upstream Bio
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $10.91
Upside: -
Ultragenyx Pharmaceutical
Oct 21, 2024
Maintains: Buy
Price Target: $61 → $73
Current: $37.43
Upside: +95.03%
Exelixis
Oct 21, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $43.53
Upside: -21.89%
Jul 23, 2024
Maintains: Buy
Price Target: $54 → $59
Current: $40.01
Upside: +47.48%
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $33.47
Upside: +100.18%
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $11.81
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $5.57
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.02
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $21.46
Upside: -
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $560.53
Upside: +14.36%
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.36
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $375 → $625
Current: $5.71
Upside: +10,845.71%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $26.91
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $20.53
Upside: +85.09%
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.51
Upside: -
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.39
Upside: -